Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1
Lumasiran treatment for up to 60 months in ILLUMINATE-A was associated with sustained reductions in UOx excretion and plasma oxalate concentration, encouraging clinical outcomes including stable eGFR in a population that would be expected to show eGFR decline, reduced kidney stone event rates, improved medullary nephrocalcinosis, and indications of improved health-related quality of life.Clinical Trial registry name and registration number: ClinicalTrials.gov NCT03681184 .
Authors
- Jaap W. Groothoff (ORCID: https://orcid.org/0000-0002-8467-3506)
- W. J. Du (ORCID: https://orcid.org/0009-0008-7319-4324)
- Cristin Kaspar (ORCID: https://orcid.org/0000-0003-2720-9325)
- John M. Gansner (ORCID: https://orcid.org/0000-0002-4030-3044)
- Julien Hogan (ORCID: https://orcid.org/0000-0003-4838-9417)
- John Charles Lieske (ORCID: https://orcid.org/0000-0002-0202-5944)
- Anne‐Laure Sellier‐Leclerc (ORCID: https://orcid.org/0000-0001-9902-0850)
- Jeffrey M. Saland (ORCID: https://orcid.org/0000-0002-8481-9210)
- Yaacov Frishberg
- Martin Coenen (ORCID: https://orcid.org/0000-0003-0439-4409)
- Sally A. Hulton
Institutions
- Mayo Clinic (US)
- Alnylam Pharmaceuticals (United States) (US)
- Inserm (FR)
- University Hospital Bonn (DE)
- Shaare Zedek Medical Center (IL)
- Hôpital Femme Mère Enfant (FR)
- Emma Kinderziekenhuis (NL)
- Assistance Publique – Hôpitaux de Paris (FR)
- Birmingham Women's Hospital (GB)
- Birmingham Children's Hospital (GB)
- Hospices Civils de Lyon (FR)
- Hôpital Robert-Debré (FR)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Journal of the American Society of Nephrology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.2215/cjn.0000000916
- Primary Topic
- Kidney Stones and Urolithiasis Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00